Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guilhem Roubaud

Showing results (21-30 of 95) with videos related to

Pageof 10
Sort By:
Critical Reviews in Oncology/Hematology|November 23, 2024
Concomitant chemotherapy in trimodal treatment of patients with muscle invasive bladder cancer: A systematic review of prospective trialsCamille Baudelin, Paul Sargos, Derek Dinart, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|September 11, 2025
Role of radiotherapy in the management of testicular cancer: Recommendations from the French society for radiation oncologyCharles Raynaud, Stéphane Supiot, Jennifer Le Guévelou, et al.
European Urology Oncology|May 16, 2024
Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial ProtocolPaul Sargos, Carine Bellera, Rita Bentahila, et al.
Journal of Negative Results in Biomedicine|November 12, 2015
Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patientsGuilhem Roubaud, Véronique Brouste, Phillipe Beuzeboc, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2024
Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancerGuilhem Roubaud, Gerhardt Attard, Martin Boegemann, et al.
Critical Reviews in Oncology/Hematology|August 5, 2019
Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancerFrédéric Amestoy, Guilhem Roubaud, Mikaël Antoine, et al.
Clinics and Research in Hepatology and Gastroenterology|March 28, 2022
Diagnostic accuracy and clinical impact of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in Positron Emission Tomography - Computed Tomography (PET-CT)-positive mediastinal lymphadenopathies in patients with thoracic or extra-thoracic malignanciesDominique Béchade, Carine Bellera, Lisa Gauquelin, et al.
Cancer Treatment Reviews|August 21, 2018
Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapyPaul Sargos, Brian C Baumann, Libni Eapen, et al.
BMC Cancer|February 19, 2018
Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancerMarina Pulido, Guilhem Roubaud, Anne-Laure Cazeau, et al.
Translational Andrology and Urology|October 28, 2016
Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?Paul Sargos, Brian C Baumann, Libni J Eapen, et al.
Pageof 10

Showing results (21-30 of 95) with videos related to

Sort By:
Pageof 10
Critical Reviews in Oncology/Hematology|November 23, 2024
Concomitant chemotherapy in trimodal treatment of patients with muscle invasive bladder cancer: A systematic review of prospective trialsCamille Baudelin, Paul Sargos, Derek Dinart, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|September 11, 2025
Role of radiotherapy in the management of testicular cancer: Recommendations from the French society for radiation oncologyCharles Raynaud, Stéphane Supiot, Jennifer Le Guévelou, et al.
European Urology Oncology|May 16, 2024
Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial ProtocolPaul Sargos, Carine Bellera, Rita Bentahila, et al.
Journal of Negative Results in Biomedicine|November 12, 2015
Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patientsGuilhem Roubaud, Véronique Brouste, Phillipe Beuzeboc, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2024
Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancerGuilhem Roubaud, Gerhardt Attard, Martin Boegemann, et al.
Critical Reviews in Oncology/Hematology|August 5, 2019
Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancerFrédéric Amestoy, Guilhem Roubaud, Mikaël Antoine, et al.
Clinics and Research in Hepatology and Gastroenterology|March 28, 2022
Diagnostic accuracy and clinical impact of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in Positron Emission Tomography - Computed Tomography (PET-CT)-positive mediastinal lymphadenopathies in patients with thoracic or extra-thoracic malignanciesDominique Béchade, Carine Bellera, Lisa Gauquelin, et al.
Cancer Treatment Reviews|August 21, 2018
Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapyPaul Sargos, Brian C Baumann, Libni Eapen, et al.
BMC Cancer|February 19, 2018
Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancerMarina Pulido, Guilhem Roubaud, Anne-Laure Cazeau, et al.
Translational Andrology and Urology|October 28, 2016
Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?Paul Sargos, Brian C Baumann, Libni J Eapen, et al.
Pageof 10